Evidence map›Paper›PMID 33190437›Full record

Trial reportZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2020

[Efficacy and safety of generic azacitidine in Chinese patients with higher-risk myelodysplastic syndromes: a multicenter, prospective, single-arm study].

H G Zhao, F Liu, T J Qin, H Bai, M Hou, K Yu, Y Hu, L Liu, Y Li, L Yu

Open access · greenAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

H G ZhaoDepartment of Hematology, The Affiliated Hospital of Qingdao University, Qingdao 266000, China.
F LiuDepartment of Hematology, Xiyuan Hospital, Chinese Academy of Medical Sciences, Beijing 100091, China.
T J QinNational Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
H BaiDepartment of Hematology, Chinese People's Liberation Army Joint Logistics Support Unit 940 Hospital, Lanzhou 730050, China.
M HouDepartment of Hematology, Qilu Hospital of Shandong University, Jinan 250012, China.
K YuDepartment of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Y HuDepartment of Hematology, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, China.
L LiuDepartment of Hematology, Tangdu Hospital, Air Force Medical University, Xi'an 710038, China.
Y LiDepartment of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
L YuDepartment of Hematology, Chinese PLA General Hospital, Beijing 100853, China; Department of Hematology-Oncology, International Cancer Center, Shenzhen University General Hospital, Shenzhen University Health Science Center, Shenzhen 518060, China.
Affiliated Hospital of Qingdao University · CNChinese PLA General Hospital · CNQilu Hospital of Shandong University · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Myelodysplastic SyndromesAntimetabolites, AntineoplasticAsian PeopleAzacitidineChinaHumansProspective StudiesTreatment OutcomeAntimetabolites, AntineoplasticAzacitidineAzacitidineClinical trials, phase Ⅲ as topicMyelodysplastic syndromesPharmacokinetics

Identifiers

PMID33190437
PMCPMC7656073
OpenAlexW3104466954

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.